CN203506763U - Intestinal biomarker sampler - Google Patents
Intestinal biomarker sampler Download PDFInfo
- Publication number
- CN203506763U CN203506763U CN201320608860.4U CN201320608860U CN203506763U CN 203506763 U CN203506763 U CN 203506763U CN 201320608860 U CN201320608860 U CN 201320608860U CN 203506763 U CN203506763 U CN 203506763U
- Authority
- CN
- China
- Prior art keywords
- biomarker
- intestinal
- inner shell
- shell
- microsphere
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000090 biomarker Substances 0.000 title claims abstract description 44
- 230000000968 intestinal effect Effects 0.000 title claims abstract description 31
- 239000004005 microsphere Substances 0.000 claims abstract description 33
- 239000003446 ligand Substances 0.000 claims abstract description 13
- 238000005070 sampling Methods 0.000 claims abstract description 9
- 108010010803 Gelatin Proteins 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 230000003044 adaptive effect Effects 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 239000012528 membrane Substances 0.000 abstract description 3
- 239000002775 capsule Substances 0.000 abstract 1
- 210000003608 fece Anatomy 0.000 description 13
- 238000010521 absorption reaction Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 description 2
- 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 description 2
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241001591005 Siga Species 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 210000005002 female reproductive tract Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Images
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The utility model discloses an intestinal biomarker sample thief, include: a shell in the form of a capsule; the inner shell is positioned in the outer shell, is matched with the shape of the outer shell and is tightly attached to the inner wall of the outer shell; a plurality of microspheres filled in the inner shell, wherein the outer surfaces of the microspheres are attached with specific ligand membranes combined with external biomarkers; and the external biomarker matched with the microsphere is adsorbed by a specific ligand membrane on the surface of the microsphere, so that the sampling of the intestinal biomarker is realized. The utility model discloses can be simple and convenient, quick, safely sample the biomarker in the excrement in the intestinal automatically.
Description
Technical field
This utility model relates to mini-medical apparatus that can be oral, particularly a kind of intestinal biomarker sampler.
Background technology
In medical treatment clinical practice, the laboratory of biomarker detects and in modern medicine, occupies very consequence.At present, existing increasing biomarker is found and is widely used in clinical practice, these biomarkers may come from tissue, organ, blood, bile, bone marrow, urine or feces etc., as the EGF-R ELISA in pulmonary adenocarcinoma (EGFR) detects the variation that can understand pulmonary carcinoma oncogene, the prognosis of direction of medication usage predicting tumors; Serum alpha-fetoprotein (AFP) horizontal detection can diagnosing primary cell carcinoma and is judged lapsing to of disease; HCG in pregnant woman urine (HCG) horizontal detection can be diagnosed early pregnancy; Excrement calprotectin content (FCC) detects can diagnose inflammatory bowel; Carcinoembryonic antigen in feces (CEA) is the biomarker of gastrointestinal tumor, and its sensitivity even detects or fecal occult blood testing higher than patients serum CEA.Because the biomarker in feces is directly excreted to feces from intestinal mucosa secretion, the pathology of direct reaction intestinal mucosa, physiological status, so by detecting some the specific biological mark in feces, the diagnosis of some intestinal tract disease is had to higher value.
Although the features such as stool examination has simply, noinvasive, cheapness, and Chang Zuowei disorder in screening or the means made a definite diagnosis.But its prerequisite is stool sample must be left and taken by strict operation, should be sent to immediately appointed place, then be transferred to laboratory or specimen center by medical personnel after leaving and taking, check as early as possible.Yet, in real work, because middle swivel link is numerous, it is different in size that feces is expelled to time of sampling, more owing to being full of stink, collection need to sample in urinal, often more difficult, and the sampling mode of this shortage strict standard limits or have influence on reliability and the accuracy of check result greatly, in order accurately to detect the biomarker in sample,, specificity and the sensitivity of raising feces biomarker, need to develop a kind of simple, quick effective and standardized sampling approach.
Utility model content
Technical problem to be solved in the utility model, is just to provide a kind of intestinal biomarker sampler, can be easy, quick, safe, automatically the biomarker in Excreta in intestinal is sampled.
For solving the problems of the technologies described above, this utility model is achieved through the following technical solutions:
An intestinal biomarker sampler, comprising: a shell, is capsule-type; One inner shell, is positioned at shell, adaptive and be close to outer casing inner wall with the shape of shell; A plurality of microspheres, are filled in inner shell, and the outer surface of described microsphere is with the ligands specific film of being combined with outside biomarker; Ligands specific film by microsphere surface adsorbs the outside biomarker with its pairing, realizes the sampling of intestinal biomarker.
Further, described inner shell is water-soluble cellulose derivative, both can protect the microsphere inner shell that do not dissociate, can make again target biology mark freely pass through its loose porous structure and with the part absorption combination of microsphere surface.For the inner shell of other polymeric material, this utility model aperture that the outside biomarker of a plurality of confessions passes through that can additionally distribute on the housing of described inner shell.And for ease of fast collect inner shell with magnetic field force, inner shell can be magnetic.
Further, for ease of filling microsphere or take out microsphere in inner shell, described inner shell is divided into cap body and inner shell body, and described cap body is removably installed on inner shell body.
Further, dissolved under one's belt for preventing shell, the outer surface of described shell scribbles one deck enteric gelatin protecting film, and it can dissolve at enteral, and does not dissolve at gastric.
Compared with prior art, the utlity model has following beneficial effect:
This utility model is shell, the capsule-type structure of inner shell and microsphere, by the protection of shell, can be not dissolved under one's belt, and be decomposed in intestinal (large intestine and small intestinal), ligands specific film by microsphere surface comes in conjunction with the target biology mark in absorption intestinal Excreta, thereby in the time of outside Excreta is discharged human body, can fast search out inner shell by magnetic field suction type or alternate manner, removable inner shell again, detect microsphere, realization is easy to biomarker, fast, safety sampling, biomarker in can fully adhering in intestinal simultaneously, thereby improve the specificity and the sensitivity that detect.
Accompanying drawing explanation
Fig. 1 is the planar structure partial schematic sectional view of this utility model sampler;
Fig. 2 is the stereochemical structure partial schematic sectional view of this utility model sampler;
Fig. 3 is the structural representation of this utility model microsphere.
In figure: 1, shell, 11, enteric gelatin protecting film, 2, inner shell, 21, aperture, 22, cap body, 23, inner shell body, 3, microsphere, 4, ligands specific film.
The specific embodiment
Below in conjunction with the drawings and specific embodiments, the utility model is described in further detail.
A kind of intestinal biomarker sampler as shown in Fig. 1～2, comprising: a shell 1, is capsule-type; One inner shell 2, is positioned at shell, is also capsule-type, adaptive with the shape of shell 1, and is close to shell 1 inwall; A plurality of microspheres 3, are filled in inner shell 2, and as shown in Figure 3, the outer surface of microsphere 3 is with the ligands specific film 4 of being combined with outside biomarker, biomarker can with ligand membrane specific binding.
Wherein, the outer surface of shell 1 scribbles one deck enteric gelatin protecting film 11, makes shell not dissolved under one's belt, and dissolves in intestinal.Thereby after dissolving in intestinal, shell 1 exposes inner shell 2.The shell 1 of the present embodiment is about 0.8cm or shorter, diameter 0.5mm or less, the about 120mm of volume
3.
As shown in Fig. 1～2, the inner shell 2 of the present embodiment is magnetic, also can be the housing of general polymer material, as fiber, plastics, plastic material.Inner shell also can be metal material, to irradiate the lower position of determining this sampler by X-ray instrument.Inner shell is not dissolved in intestinal; through Laser Processing aperture 21; aperture is less than 20 μ m; form loose structure; both can splendid attire, protection microsphere 3; its larger volume is also beneficial in Excreta and finds, thereby this inner shell 2 can make again target biomarker freely pass through the structure of its porous and the 4 absorption combinations of the ligands specific film on microsphere 3 surfaces.In addition, inner shell 2 also can adopt water-soluble cellulose derivative material, itself has loose porous structure, not dissolved in intestinal.
As shown in Fig. 1～2, inner shell 2 is divided into cap body 22 and inner shell body 23, and cap body 22 is removably installed on inner shell body 23, and the cap body 22 of the present embodiment and inner shell body 23 are provided with the Access Division that clamping coordinates, and can cover by convenient plug-in mounting.Open cap body 22, can fill new microsphere 3, also can take out with intestinal internal target biomarker specific binding after microsphere 3.
By the ligands specific film 4 on microsphere 3 surfaces, screen the outside biomarker of absorption and its pairing, realize the sampling of biomarker.After the inner shell 2 that is loaded with microsphere 3 is discharged with Excreta, available magnetic field fast searching is to its position, and separated with Excreta.The ligands specific film 4 that microsphere 3 surface coverage adhere to, can be a-protein/G/L-immunoglobulin, Ag-Ab, it has stronger adhesion, can identify very soon the target biology mark in intestinal, secretory IgA, sIgA for example, calprotectin, lactoferrin, pathogen antigen etc., then take out microsphere 3 use SDS-PAGE, ELISA and protein groups technical Analysis, reflection disease symptoms.
In addition, microsphere 3 can coat and be different from excremental other color, is convenient to find; Also microsphere can be arranged to magnetic, be convenient to magnetic field force and find.Microsphere can be used to the antibody of covalent coupling biomarker simultaneously.Sampler of the present utility model also can be used to the biomarker sampling of mouth, conjunctival sac and female genital tract.
Embodiment of the present utility model is not limited to this; according to foregoing of the present utility model; utilize ordinary skill knowledge and the customary means of this area; do not departing under the above-mentioned basic fundamental thought of this utility model prerequisite; this utility model can also be made modification, replacement or the change of other various ways, within all dropping on this utility model rights protection scope.
Claims (7)
1. an intestinal biomarker sampler, is characterized in that, comprising:
One shell, is capsule-type;
One inner shell, is positioned at shell, adaptive and be close to outer casing inner wall with the shape of shell;
A plurality of microspheres, are filled in inner shell, and the outer surface of described microsphere is with the ligands specific film of being combined with intestinal biomarker;
Ligands specific film by microsphere surface adsorbs the intestinal biomarker with its pairing, realizes the sampling of intestinal biomarker.
2. intestinal biomarker sampler according to claim 1, is characterized in that: described inner shell is water-soluble cellulose derivative.
3. intestinal biomarker sampler according to claim 1, is characterized in that: on the housing of described inner shell, be distributed with the aperture that the outside biomarker of a plurality of confessions passes through.
4. intestinal biomarker sampler according to claim 3, is characterized in that: described inner shell is magnetic.
5. according to the intestinal biomarker sampler described in claim 2-4 any one, it is characterized in that: described inner shell is divided into cap body and inner shell body, described cap body is removably installed on inner shell body.
6. intestinal biomarker sampler according to claim 1, is characterized in that: the outer surface of described shell scribbles one deck enteric gelatin protecting film.
7. intestinal biomarker sampler according to claim 1, is characterized in that: described microsphere is magnetic.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201320608860.4U CN203506763U (en) | 2013-09-29 | 2013-09-29 | Intestinal biomarker sampler |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201320608860.4U CN203506763U (en) | 2013-09-29 | 2013-09-29 | Intestinal biomarker sampler |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN203506763U true CN203506763U (en) | 2014-04-02 |
Family
ID=50365752
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201320608860.4U Expired - Lifetime CN203506763U (en) | 2013-09-29 | 2013-09-29 | Intestinal biomarker sampler |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN203506763U (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103479401A (en) * | 2013-09-29 | 2014-01-01 | 中山大学附属第一医院 | Intestinal biomarker sampler |
-
2013
- 2013-09-29 CN CN201320608860.4U patent/CN203506763U/en not_active Expired - Lifetime
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103479401A (en) * | 2013-09-29 | 2014-01-01 | 中山大学附属第一医院 | Intestinal biomarker sampler |
| CN103479401B (en) * | 2013-09-29 | 2015-08-19 | 中山大学附属第一医院 | Intestinal biomarker sampler |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6619886B2 (en) | Smart toilet that can monitor stool | |
| US10827953B2 (en) | Devices, systems and methods for in-vivo immunoassay | |
| CN101221180B (en) | Portable fast joint inspection device for multiple tumor marker | |
| BRPI0902559A2 (en) | high sensitivity multiparameter method for rare event analysis in a biological sample | |
| CN109628277A (en) | The separation of excretion in-vivo tumour mark miRNA a kind of and detection system and method | |
| KR20220050844A (en) | Method for Diagnosing a Disease Using Morphology of Luterial | |
| CN103479401B (en) | Intestinal biomarker sampler | |
| CN103487493A (en) | Applications of urine molecule | |
| CN106680515B (en) | It is combined for the polymolecular marker of pulmonary cancer diagnosis | |
| Gude et al. | Colorectal Cancer Diagnostic Methods: The Present and Future | |
| CN203506763U (en) | Intestinal biomarker sampler | |
| US20200049700A1 (en) | Nanoparticle-enhanced enzymatic immune biosensor assay for antigen detection | |
| Zhao et al. | Developing sensor materials for screening intestinal diseases | |
| CN107144688B (en) | CD19 positive excretion bodies are as application of the molecular labeling in preparing tumor diagnosis kit and kit | |
| CN202305531U (en) | Fecal occult blood detecting device | |
| CN201196650Y (en) | Portable fast joint inspection device for multiple tumor tokens | |
| AU2006242054A1 (en) | Method for determining the stage of ulcerative colitis or interstitial pneumonitis and reagent kit thereof | |
| CN109085355A (en) | Serum protein markers combine the application in screening lung cancer and diagnosis and treatment | |
| CN109085359A (en) | Serum protein markers combine the application in colorectal cancer screening and diagnosis and treatment | |
| CN210401430U (en) | Fecal occult blood detection device | |
| KR20010034791A (en) | Method for producing a specific antiserum against the univesal tumorous antigen and method for diagnosing malignant tumours using said antiserum | |
| CN207007856U (en) | The kit of hemoglobin in a kind of quick detection excrement | |
| KR20170047151A (en) | A device for the self-assessment of periodontitis and metabolic syndrome | |
| Javaed | Gender prevalence in celiac disease | |
| CN109212185A (en) | One-step method pepsinogen Cgene quick detection kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| AV01 | Patent right actively abandoned |
Granted publication date: 20140402 Effective date of abandoning: 20150819 |
|
| AV01 | Patent right actively abandoned |
Granted publication date: 20140402 Effective date of abandoning: 20150819 |
|
| RGAV | Abandon patent right to avoid regrant |